Patents Assigned to ScandiEdge Therapeutics AB
  • PKLR inhibition in the treatment of NAFLD and HCC
    Patent number: 11034960
    Abstract: There is provided a medical agent for use in a method of treatment of nonalcoholic fatty liver disease (NAFLD) or hepatocellular carcinoma (HCC), wherein the medical agent comprises a polynucleotide and is capable of silencing or knocking out the PKLR gene.
    Type: Grant
    Filed: August 14, 2018
    Date of Patent: June 15, 2021
    Assignee: ScandiEdge Therapeutics AB
    Inventors: Adil Mardinoglu, Jan Borén, Mathias Uhién